# US 2021/0171659 A1 · FGF21 Mimetic Antibodies and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171659 A1
- Document ID: US20210171659A1
- Status: Published application
- Kind: A1
- Application number: 17/127,600
- Filed: 2020-12-18
- Published: 2021-06-10
- Earliest claimed: 2017-02-08
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Regis Cebe; Stephane Olland; David Langdon Yowe
- Web page: https://patentgrep.com/patent/US20210171659A1

## CPC

- C07K 16/40: against enzymes
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human β-klotho, and pharmaceutical compositions and methods of treatment comprising the same.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A nucleic acid coding for an antibody or antigen-binding fragment thereof that binds to β-klotho, comprising the nucleotide sequences encoding the heavy chain variable region as set forth in SEQ ID NOs: 16, 36, or 38; and the light chain variable region as set forth in SEQ ID Nos: 54, 27, 33, or 40.

### Claim 22 (depends on 21)

The nucleic acid of claim 21, wherein the nucleotide sequences encode the heavy chain as set forth in SEQ ID Nos: 18, 37, 30, or 39; and the light chain as set forth in SEQ ID Nos: 29, 51, 35 or 41.

### Claim 23 (depends on 21)

A vector comprising the nucleic acid according to claim 21.

### Claim 24 (depends on 23)

A host cell comprising the vector of claim 23.

### Claim 25 (depends on 24)

A method of making an antibody or antigen-binding fragment thereof which binds β-klotho, comprising the step of culturing the host cell of claim 24 under conditions suitable for expression of the antibody or a fragment thereof.

### Claim 26 (depends on 21)

The nucleic acid of claim 21, comprising the nucleotide sequences in the heavy chain variable region as set forth in SEQ ID NOs: 16 or 36; and in the light chain variable region as set forth in SEQ ID Nos: 54 or 27.

### Claim 27 (depends on 21)

The nucleic acid of claim 21, comprising the nucleotide sequences in the heavy chain variable region as set forth in SEQ ID NOs: 16 or 38; and in the light chain variable region as set forth in SEQ ID Nos: 33 or 40.

### Claim 28 (depends on 21)

The nucleic acid of claim 21, comprising the nucleotide sequence in the heavy chain region as set forth in SEQ ID Nos: 18 or 37; and in the light chain region as set forth in SEQ ID Nos: 29 or 51.

### Claim 29 (depends on 21)

The nucleic acid of claim 21, comprising the nucleotide sequence in the heavy chain region as set forth in SEQ ID Nos: 30 or 39; and in the light chain region as set forth in SEQ ID Nos: 35 or 41.

### Claim 30 (depends on 26)

A method of making an antibody or antigen-binding fragment thereof which binds β-klotho, comprising the step of culturing a host cell comprising a vector comprising the nucleic acid of claim 26.

### Claim 31 (depends on 27)

A method of making an antibody or antigen-binding fragment thereof which binds β-klotho, comprising the step of culturing a host cell comprising a vector comprising the nucleic acid of claim 27.

### Claim 32 (depends on 28)

A method of making an antibody or antigen-binding fragment thereof which binds β-klotho, comprising the step of culturing a host cell comprising a vector comprising the nucleic acid of claim 28.

### Claim 33 (depends on 29)

A method of making an antibody or antigen-binding fragment thereof which binds β-klotho, comprising the step of culturing a host cell comprising a vector comprising the nucleic acid of claim 29.
